Ju Dong Yang MD
Biliary Tract Disease, Gastrointestinal Cancer, Hepatology & Liver Transplantation
Physician
Join to View Full Profile
8700 Beverly BlvdWest Hollywood, CA 90048
Phone+1 310-423-6000
Fax+1 310-423-2356
Dr. Yang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Transplant Hepatology, 2018 - 2018- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 2014 - 2017
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2011 - 2014- Mayo Clinic College of MedicinePost-Doctoral Fellowship, 2009 - 2011
OtherClass of 2005, MD
Certifications & Licensure
CA State Medical License 2018 - 2026
MN State Medical License 2014 - 2019
AR State Medical License 2013 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Transplant Hepatology
Clinical Trials
- Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study Start of enrollment: 2021 May 11
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial ...Wee Han Ng, Yee Hui Yeo, Hyunseok Kim, Ekihiro Seki, Jonathan Rees
Hepatology. 2025-04-02 - Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation.Joseph C Ahn, Wee Han Ng, Yee Hui Yeo, Hyun-Seok Kim, Yun Wang
Hepatology. 2025-03-28 - Agile 3+ and 4 Scores Accurately Predict Major Adverse Liver Outcomes, Liver Transplant, Progression of MELD Score, the Development of Hepatocellular Carcinoma, and De...Emily Truong, Lynna Alnimer, Jeffrey A Gornbein, Ju Dong Yang, Naim Alkhouri
Digestive Diseases and Sciences. 2025-03-24
Press Mentions
Acceptable Liver Transplant Outcomes Seen After ICI Therapy for Liver CancerAugust 19th, 2024- Acceptable Liver Transplant Outcomes Seen After ICI Therapy for Liver CancerAugust 19th, 2024
- Study: Transplant Possible After Immunotherapy for Advanced Liver Cancer PatientsAugust 8th, 2024
Grant Support
- Novel circulating biomarker digital scores for assessing treatment response in liver cancerCEDARS-SINAI MEDICAL CENTER2023–2025
- Novel circulating biomarker digital scores for assessing treatment response in liver cancerCEDARS-SINAI MEDICAL CENTER2022–2025
- Novel circulating biomarker digital scores for assessing treatment response in liver cancerCEDARS-SINAI MEDICAL CENTER2022–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
